Ozempic and Wegovy are two anti-obesity drugs that have been proven to be effective in reducing weight in their users. Although this GLP-1-based drug was originally developed for diabetes patients, it also has a positive impact on reducing appetite, reducing hunger and can be used to fight addiction.
After years of offering Wegovy in injection form, Novo Nordisk announced that they have received FDA approval to offer it in pill form in the United States starting in 2026. This 1.5 mg pill must be taken once a day.
In clinical trials involving 300 participants, pill takers managed to lose an average of 16.6% of their weight in 6 weeks. Its effectiveness is the same as Wegovy with a 2.4 mg injection. The side effects of the pill version are still the same as the injection version, namely nausea, diarrhea, vomiting and constipation.
The advantage of the pill version of Wegovy is that it does not require injections and can be stored without having to be frozen. In the United States, a supply of Wegovy in pill form is sold for $149 (~RM 604) for a month's supply.
